These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 27432383)

  • 41. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
    Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis.
    Deguchi H; Yamazaki H; Kamitani T; Yamamoto Y; Fukuhara S
    Adv Ther; 2021 Jul; 38(7):3937-3947. PubMed ID: 34091865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
    Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
    Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
    Li X; Liu Y; Wang M; Gao L; Liu J; Zhang H; Wu M; Chen H; Lou J; Wang J; Chen J; Geng G; Ma Z; Ding Y
    Lancet Infect Dis; 2024 Jun; 24(6):650-664. PubMed ID: 38359854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
    Graham DY
    Dig Dis Sci; 2023 May; 68(5):1691-1697. PubMed ID: 36856926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two vonoprazan combinations (Voquezna) for H. pylori.
    Med Lett Drugs Ther; 2022 Oct; 64(1662):169-172. PubMed ID: 36383768
    [No Abstract]   [Full Text] [Related]  

  • 51. Safety and effectiveness of vonoprazan-based rescue therapy for
    Yu J; Lv YM; Yang P; Jiang YZ; Qin XR; Wang XY
    World J Gastroenterol; 2023 May; 29(20):3133-3144. PubMed ID: 37346155
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
    Tsay FW; Wu DC; Kao SS; Tsai TJ; Lai KH; Cheng JS; Chan HH; Wang HM; Tsai WL; Tseng HH; Peng NJ; Hsu PI
    Helicobacter; 2015 Feb; 20(1):71-7. PubMed ID: 25495272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
    Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
    Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Takara Y; Endo H; Nakano R; Kawachi K; Hidaka H; Matsunaga T; Tsuruoka N; Sakata Y; Shimoda R; Hara M; Fujimoto K
    Digestion; 2019; 99(2):172-178. PubMed ID: 30179876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
    Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
    Lee H; Kim BJ; Kim SG; Kim JI; Choi IJ; Lee YC; Kim JG; Kim JJ;
    Trials; 2017 Nov; 18(1):549. PubMed ID: 29149904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
    Jenkins H; Jenkins R; Patat A
    Clin Drug Investig; 2017 Mar; 37(3):311-316. PubMed ID: 27928738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country.
    Fischbach LA; Bravo LE; Zarama GR; Bravo JC; Ojha RP; Priest EL; Collazos T; Casabon AL; Guerrero LZ; Singh KP; Correa P
    Helicobacter; 2009 Apr; 14(2):100-8. PubMed ID: 19298337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.